why choose us

First received: December 06, 2022

Clinical Trial: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Refractory Neuroblastoma

Study Type: INTERVENTIONAL


Official Title: Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma

Brief Summary: This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma.

Read more